AeroRx Therapeutics announced that it has closed a $21 million Series A financing to support continued development of the company’s AERO-007 indacaterol / glycopyrrolate inhalation solution for the treatment of COPD. In 2022, AeroRx announced that it was developing a nebulized LABA/LAMA inhalation solution that would be delivered via HCMed’s AdheResp breath-actuated device, and earlier this year, the company reported positive results from a Phase 2a trial of AERO-007 in COPD patients.
AeroRx Therapeutics CEO Ahmet Tutuncu commented, “With this Series A financing, we are well positioned to advance AERO-007 into a Phase 2b dose optimization study and prepare for late-stage, NDA-enabling development. Our Phase 2a study data further support AERO-007’s potential as a once-daily nebulized LABA/LAMA combination, designed to address a major unmet need for underserved COPD patients.”
Jay Lichter, Managing Partner at lead investor Avalon BioVentures said, “Dual bronchodilation via handheld inhalers is the standard of care, but millions of patients remain poorly controlled due to difficulties with inhaler technique. AeroRx has the opportunity to deliver meaningful clinical benefit by bringing the preferred guideline therapy to patients in a nebulized form that is designed for full dosing and improved adherence.”
Read the AeroRx Therapeutics press release
